You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKinsey
Colorcon
Mallinckrodt
Express Scripts

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

ERBITUX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ERBITUX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Azienda Unità Sanitaria Locale Reggio EmiliaPhase 3
Istituto Di Ricerche Farmacologiche Mario NegriPhase 3
Istituto Nazionale Tumori IRCCS - Fondazione G. PascalePhase 3

See all ERBITUX clinical trials

Recent Litigation for ERBITUX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Ravgen, Inc. v. Myriad Genetics, Inc.2020-12-20
Ravgen, Inc. v. Ariosa Diagnostics, Inc.2020-12-02

See all ERBITUX litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-09-14
Forty Seven, Inc.2018-01-08

See all ERBITUX litigation

Pharmacology for ERBITUX
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for ERBITUX

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Get Started for $10 Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) 2018-04-17 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ERBITUX

These patents were identified by searching patent claims

Supplementary Protection Certificates for ERBITUX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
301021 Netherlands   Get Started for $10 PRODUCT NAME: TALAZOPARIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1377 20190624
28/2020 Austria   Get Started for $10 PRODUCT NAME: POLATUZUMAB VEDOTIN; REGISTRATION NO/DATE: EU/1/19/1388 (MITTEILUNG) 20200120
122019000108 Germany   Get Started for $10 PRODUCT NAME: TALAZOPARIB ODER PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1377 20190620
122008000030 Germany   Get Started for $10 PRODUCT NAME: PANITUMUMAB MIT WENIGSTENS EINEM WIRKSTOFF AUSGEWAEHLT AUS IRINOTECAN, CISPLATIN, 5-FLUOROURACIL, GEMCITABIN, PACLITAXEL UND CARBOPLATIN; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
301056 Netherlands   Get Started for $10 PRODUCT NAME: POLATUZUMAB VEDOTIN; REGISTRATION NO/DATE: EU/1/19/1388 20200120
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
Medtronic
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.